|Bid||0.00 x 172000|
|Ask||0.00 x 167600|
|Day's Range||41.06 - 43.47|
|52 Week Range||25.91 - 48.10|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||80.06|
|Forward Dividend & Yield||0.31 (0.74%)|
|Ex-Dividend Date||Aug 30, 2021|
|1y Target Est||N/A|
Japan's Nikkei share average rose to a one-month closing high on Monday, tracking a rally on Wall Street as a positive analysis on a potential COVID-19 drug offset investor fears over surging virus cases. The benchmark Nikkei share average settled 2.22% higher at 22,784.74, its highest close since June 10, also helped by gains in auto stocks on upbeat industry data from China. U.S. stocks gained on Friday as Gilead Sciences Inc's antiviral remdesivir showed reduced risk of death in severely ill COVID-19 patients, but the company cautioned rigorous clinical trials were needed to confirm the benefit.
Japanese shares closed at a one-week low on Friday as a spike in fresh COVID-19 cases at home and abroad fuelled concerns that the path to economic recovery could be hindered, while the market braced for further corporate earnings pain. More than 60,500 new COVID-19 infections were reported across the United States on Thursday, the largest single-day tally record, stoking fears that new lockdowns could take a toll on the economic recovery. Hideyuki Ishiguro, senior strategist at Daiwa Securities in Tokyo, said investors also awaited earnings report from Yaskawa Electric Corp due later in the day.
Japanese shares bounced back on Thursday buoyed by technology-related stocks following a rise in U.S. peers overnight, but gains were limited by a surge in domestic coronavirus cases. The benchmark Nikkei share average rose 0.4% to 22,529.29, clawing back from a 0.78% drop in the previous session. On the Nikkei index, there were 63 advancers against 158 decliners.